RxDoctor Payments Data

Brandon Banks, MD

Pain Medicine · Monroe, LANPI 1326485426

Payments from drug & device makers

What this record shows

19 manufacturers reported payments, led by Boston Scientific at 35.2% of the total. Reporting peaked in 2019 at $2,004 and has fallen 91.4% since, to $172 in 2024.

$5,655in general payments, 2019–2025

Across 119 payments — averaging $47.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$1K
  • Stryker$798
  • Curonix LLC$268
  • Nevro Corp.$252
  • Abbott$166
  • plus $803 from 13 others

What the payments were for

  • Travel & lodging$2,43343%
  • Food & beverage$3,22257%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,655 in reported general payments places this provider in the 65th percentile of 97 pain medicine providers in Louisiana.

See all pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$173,504
Medicare patients
355
Services billed
1,871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,570$36,438
OxycontinOxycodone Hcl11$15,046
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen503$14,663
Xtampza ErOxycodone Myristate23$10,268
Buprenorphine27$4,373
Gabapentin471$4,145
Pregabalin162$3,274
Oxycodone Hcl153$3,222
Celecoxib150$2,432
Tramadol Hcl ErTramadol Hcl30$1,867
Tizanidine Hcl297$1,845
Diclofenac Sodium94$1,818
Tramadol Hcl209$1,447
Methocarbamol148$1,438
Fentanyl18$1,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$144$10,26823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 97 pain medicine providers in Louisiana.

Other pain medicine in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →